$ALEC News

Alector: Maintaining "Hold" ABC Platform Transition And GCase Partnership With Roche

Alector stock surges 13% on premium-priced equity offering

Alector Announces Pricing of Underwritten Offering

Alector (ALEC) Stock Fair Value Rises After Genentech Deal Draws Split Analyst Views

Alector, Inc. (ALEC) Discusses Strategic Advances in Next Generation Neurodegeneration Therapies and Pipeline Developments - Slideshow

HC Wainwright & Co. Maintains Buy on Alector, Raises Price Target to $8

Alector Maps Brain-Delivery Pipeline for Alzheimer’s, Parkinson’s Therapies

Alector, Inc. (ALEC) Discusses Strategic Advances in Next Generation Neurodegeneration Therapies and Pipeline Developments Transcript

Alector to Host Virtual Research and Development Event Highlighting Wholly Owned Alector Brain Carrier (ABC)- Enabled Pipeline

Morgan Stanley Maintains Underweight on Alector, Raises Price Target to $3

Alector shares up after sealing $1.27bn Roche Parkinson’s disease license deal

Alector Signs $1.27 Billion Genentech License Agreement for Parkinson’s Disease Program

Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy for Parkinson’s Disease and Other Neurodegenerative Diseases

Alector Teams Up With Genentech On Potential Parkinson’s Treatment

Alector, Inc. (ALEC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Alector, Inc. (ALEC) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Prepared Remarks Transcript

Alector to Participate in Upcoming Healthcare Conferences

Alector Reports Second Quarter 2026 Financial Results and Provides Business Update

GSK ends brain drug alliance with Alector

GSK Walks Away From Alector - Pipeline Reset Story Begins